Soolantra is the U.S. prescription brand for ivermectin cream, 1%, a topical medicine indicated for inflammatory lesions of rosacea. Its label identifies a facial cream, not a tablet, a head-lice lotion or a general-purpose skincare product. The 1% concentration refers to ivermectin in the cream formulation: each gram contains 10 mg of the active ingredient. Recognizing the exact formulation is important because products containing ivermectin can have very different purposes, instructions and rules for obtaining them.
The brand name Soolantra identifies a particular U.S. drug product and its labeling. Ingredient-named ivermectin cream 1% products are also available as FDA-approved generics, but a pharmacy listing should still be checked for the exact strength, dosage form, manufacturer or labeler and prescription requirements. A familiar brand name does not confirm that a given tube size is currently stocked, and an FDA product record should not be mistaken for a live inventory report. This page explains the brand and its U.S. product identity rather than ranking sellers or promising access.
For a broader overview of the ingredient-based category, see ivermectin cream 1% products. If the main question is how to fill a prescription for this specific brand, Soolantra pharmacy access covers that separate process. Here the focus remains on what Soolantra is, what its approved label actually says, how to recognize the branded product and where the boundaries lie between Soolantra, generic cream and other rosacea therapies.
Soolantra is a branded, human-use prescription cream whose active ingredient is ivermectin. The prescribing label describes a white-to-pale-yellow cream for topical application to affected facial skin. It is not interchangeable with an oral ivermectin tablet simply because both share an ingredient, and it should not be confused with OTC ivermectin lotion 0.5% for head lice. These distinctions are central when interpreting a pharmacy search result that shows several formulations under the same ingredient name.
The U.S. brand labeling identifies Galderma Laboratories, L.P. in the product information. The FDA-labeled purpose is treatment of inflammatory lesions of rosacea, and the cream strength is 1%. Packaging presentations are listed in the label, but the sizes in an official document are historical or regulatory product facts rather than a guarantee of availability at a pharmacy today. A patient should match the actual prescription and dispensing label to the exact cream that a pharmacist supplies.
The quick-reference table captures product facts that help identify Soolantra without substituting for the full prescribing information. For broader context about prescription and OTC skin products containing ivermectin, see the topical ivermectin product overview. A product’s active ingredient, formulation and labeled purpose must agree before a brand or generic comparison is meaningful.
| Brand detail | U.S. label information | What to verify at a pharmacy |
|---|---|---|
| Product name | Soolantra (ivermectin) cream | Name of the product actually dispensed |
| Strength and form | 1% topical cream (10 mg ivermectin per gram) | Cream 1%, not lotion 0.5% or oral tablets |
| Labeled indication | Inflammatory lesions of rosacea | Prescription and clinician assessment match the intended use |
| Regulatory access | Prescription (Rx) | Valid prescription and licensed dispensing pharmacy |
| Brand labeling | Galderma Laboratories, L.P. | Labeler, package identifiers and patient information |
| Label-listed tubes | 30 g, 45 g and 60 g | Confirm the prescribed and offered tube; listed sizes do not establish stock |
Rosacea describes a group of facial findings that can include inflammatory bumps, pustules, flushing and persistent redness. Soolantra’s FDA-labeled indication is narrower: treatment of inflammatory lesions of rosacea. A product described as a rosacea cream is therefore not automatically a treatment for every manifestation of the condition. Questions about a diagnosis, associated eye symptoms or another cause of facial irritation require clinical assessment rather than inference from the label on a tube.
Soolantra should not be presented as an FDA-approved cure for ordinary acne, perioral dermatitis or general redness unrelated to inflammatory rosacea lesions. Research on Demodex mites and hypotheses about how ivermectin may influence rosacea do not expand the authorized indication. The prescribing information states that the precise mechanism by which Soolantra treats rosacea lesions is unknown. A proposed biological explanation cannot be used as a promise of mite eradication or guaranteed clinical results.
Readers looking for disease-context discussion rather than brand identity can follow ivermectin and rosacea. Related questions about ivermectin and Demodex belong in a separate evidence-focused context. On this brand page, the central distinction is the approved claim: inflammatory lesions of rosacea, using a prescription facial cream with its own instructions and cautions.
When reviewing a Soolantra listing or pharmacy label, start with the product name, the ivermectin concentration and the dosage form. A correct brand description should identify a topical cream at 1%, rather than ivermectin lotion for the scalp or an oral product. Brand packaging may show product-specific codes and manufacturer or labeler information. The National Drug Code (NDC) is a useful package identifier, although a code shown on an old webpage does not establish that a particular package is currently marketed or stocked.
The Soolantra prescribing label lists 30 g, 45 g and 60 g tubes, with corresponding package-level NDC information. Those details can help distinguish documented branded presentations from generic cream records. They should not be converted into a claim that all sizes are routinely available or that a seller can fill any requested quantity. If the pharmacy offers a different presentation, the pharmacist can explain whether the product matches the prescription and how the package was identified.
A pharmacy may display the original prescribed brand in an electronic record even if a generic is dispensed under applicable rules. For that reason, the name shown in an online account is not always sufficient to determine what the patient will receive. The dispensed carton or tube, pharmacy label, quantity and active ingredient should be reviewed together. For a cream-focused checklist covering generic identifiers as well, consult the ingredient-based product guide for cream 1%.
Soolantra is intended for topical use on affected areas of the face. The U.S. prescribing instructions describe once-daily application, using a pea-size amount for each affected facial area such as the forehead, chin, nose or cheeks and spreading it as a thin layer. These are label facts rather than a personalized recommendation or a reason to change a clinician’s instructions. A prescribing professional should address how the treatment fits with the patient’s diagnosis, skin condition and other products already used.
The cream is not intended for oral, ophthalmic or intravaginal use. Its directions tell patients to avoid contact with the eyes and lips, and the patient information provides practical handling guidance for the tube. Someone who is uncertain about an application area, experiences an unexpected reaction or has questions about other topical medicines should consult the prescriber or pharmacist. An over-the-counter lotion used for scalp lice cannot replace this facial rosacea prescription, even though both contain ivermectin.
Treatment expectations also deserve care. A medication’s labeled schedule does not promise a particular speed or completeness of improvement, and changes in rosacea symptoms may call for follow-up rather than self-directed increases in application. Product-specific instructions take priority over simplified advice in commercial listings. The separate cream versus lotion comparison explains why two topical ivermectin products cannot be chosen merely by comparing the percentages printed on their packages.
FDA-approved generic ivermectin cream 1% belongs to the same active-ingredient and dosage-form category as Soolantra. A generic application is evaluated under FDA requirements that address product quality and, where applicable, equivalence to the reference listed drug. However, approved products can have different labeling companies, inactive ingredients, tube presentations and package identifiers. The fact that two labels state ivermectin 1% does not by itself document every detail of the approval or the substitution status for a particular package.
A pharmacist can identify the product actually available and determine whether it may be substituted under the prescription and applicable state rules. The FDA Orange Book is the appropriate regulatory framework for reviewing therapeutic equivalence information; packaging images or advertising language alone are not reliable substitutes. Patients with concerns about cream-base ingredients or previous skin reactions should raise them before a substitution, rather than assuming the brand and every generic have identical inactive components.
The brand comparison deserves a different page because the decision involves more than simply defining Soolantra. See Soolantra versus generic ivermectin cream for the side-by-side distinctions. On this page, the essential message is that the ingredient and strength connect the products, whereas FDA records, individual package labels, pharmacy substitution rules and actual supply determine what a particular prescription may be filled with.
Soolantra is a prescription medicine in the United States. An appropriate prescribing decision follows medical evaluation of the patient’s skin symptoms and treatment history; a brand listing on a website cannot establish eligibility. The same prescription requirement generally applies to the generic ivermectin cream 1% category. An online offer suggesting that the prescription facial cream is universally available over the counter deserves scrutiny, especially when it mixes the product with OTC ivermectin lice lotion.
Pharmacies check a valid prescription, the exact strength and form, any substitution instructions and the specific item selected for dispensing. A pharmacist may need to clarify the intended brand, offered generic or amount supplied. The practical purchasing details—such as how to select a dispensing channel and review a prescription fill—belong on the dedicated Soolantra pharmacy-access page, while buying prescription ivermectin cream addresses the ingredient-based category without requiring a particular brand.
The presence of a brand in an official database does not tell a consumer whether it can be picked up locally or delivered. Retail availability depends on the pharmacy, its distributors and the precise prescribed package. A licensed pharmacist can also explain whether a proposed alternative corresponds to the prescribed medicine. For the general distinction between clinician authorization and over-the-counter products, review ivermectin prescription requirements.
The U.S. Soolantra label reports local reactions including skin burning and irritation in controlled studies, and postmarketing reports have included contact dermatitis and allergic dermatitis. Such information is a reason to read the patient labeling and seek advice about persistent or concerning symptoms; it is not a prediction that a particular individual will have a reaction. The absence of a listed contraindication in the label does not mean that every patient, skin condition or concurrent treatment is suitable without a clinical discussion.
The label also addresses circumstances in which evidence is limited. Available pregnancy data are insufficient to establish a drug-associated risk, and information about transfer into human milk after topical use is limited. Safety and effectiveness in pediatric patients have not been established. Questions about pregnancy, breastfeeding, pediatric use, a history of sensitivity to cream ingredients or worsening skin findings warrant individualized guidance from a qualified clinician.
A product intended for the face should not be taken by mouth or applied to the eyes or other sites excluded by the label. Animal ivermectin preparations are not substitutes for regulated human topical medicines. Patients should also tell their prescriber about other skin preparations used on the same areas, because tolerance and treatment planning may differ. For the broader distinction between oral and topical ivermectin safety, see general ivermectin safety.
A clinician managing inflammatory rosacea may consider different topical or systemic medications depending on symptoms, previous therapy and tolerability. Soolantra is one named product in that landscape, not a universal replacement for every other prescription. Comparisons with metronidazole or azelaic acid involve different active ingredients and formulations; a comparison with doxycycline also crosses a topical-versus-oral treatment distinction. These choices are clinical questions rather than simple brand-name substitutions.
For readers who are actively comparing treatment categories, separate pages examine Soolantra versus metronidazole, Soolantra versus azelaic acid and Soolantra versus doxycycline. These comparisons help clarify forms, labeled purposes and prescribing considerations; they do not imply that one medicine is categorically superior for every case or that an individual should switch treatment without an assessment.
The brand overview remains deliberately narrower. It establishes what Soolantra contains, its U.S. rosacea indication and how to recognize its labeling. A side-by-side alternatives discussion can then start from an accurate description of the branded product rather than assumptions based on search snippets. Neither the existence of an alternative nor the active ingredient in Soolantra is enough to determine treatment suitability without knowing the type and severity of the patient’s symptoms.
The amount a person may pay for Soolantra depends on the precise product offered, prescribed quantity, pharmacy, payment method and any applicable insurance benefit. A brand-name request can produce a different result from a generic ivermectin cream request even when the active ingredient and strength are the same. Coverage rules and pharmacy contracts can change, so neither an old coupon screenshot nor a catalog listing is reliable proof of the amount owed at the register.
A useful discussion with a licensed pharmacy can focus on whether the named brand is available, what exact tube is quoted, whether a covered generic alternative may be dispensed and how the claim would be processed. A price inquiry should distinguish the brand from a generic rather than silently substituting one for the other. For an evergreen framework devoted to the brand, see Soolantra price factors; for formulary and benefit questions, see Soolantra insurance coverage.
Soolantra should be evaluated as a regulated prescription product, not as a cosmetic cream with guaranteed online availability. Before relying on any commercial listing, confirm the active ingredient, 1% cream formulation, the exact intended package and the identity of the dispensing pharmacy. Those checks are more durable than time-sensitive advertised prices or inventory claims, and they help keep brand identity, clinical decision-making and purchase logistics appropriately separate.
Soolantra is a U.S. prescription brand of ivermectin cream 1% for topical use. It is indicated for inflammatory lesions of rosacea. It is different from oral ivermectin tablets and the OTC ivermectin lotion 0.5% used for head lice.
The FDA-labeled indication is treatment of inflammatory lesions of rosacea. That does not mean the cream is approved for every form of redness, flushing, eye symptom or skin irritation associated with rosacea.
Yes. Soolantra cream 1% is a prescription product. A qualified clinician decides whether it is appropriate, and a licensed pharmacy verifies the prescription before dispensing.
They share ivermectin as the active ingredient at the same concentration. FDA-approved generic products are reviewed under generic drug standards, but packaging, inactive ingredients and labelers can differ. A pharmacist can explain the specific product and applicable substitution rules.
No. The U.S. labeled indication is inflammatory lesions of rosacea. Other skin conditions should not be treated as approved uses simply because some symptoms look similar.
The precise mechanism of action of Soolantra in treating rosacea lesions is not established in its U.S. prescribing information. Its approved indication should not be converted into a guarantee of Demodex eradication or another outcome.
No. Soolantra is prescription cream 1% for inflammatory rosacea lesions on facial skin. OTC ivermectin lotion 0.5% is a different formulation labeled for head lice. Their uses and directions are not interchangeable.
The prescribing label describes applying a thin layer to affected facial areas once daily, using a pea-size amount for each affected area, while avoiding the eyes and lips. Patients should follow their own prescription instructions and consult a clinician with application questions.
Local skin burning and irritation are described in clinical-trial labeling, and contact or allergic dermatitis has been reported after marketing. Anyone experiencing significant or persistent symptoms should seek advice from the prescriber or pharmacist.
No. An official drug label establishes product information, not present-day local inventory. The exact brand, strength, tube and dispensing options must be checked with a licensed pharmacy.